ClinicalTrials.gg
CompletedNCT06326814Updated Mar 22, 2024

A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults

A Phase 1 interventional study of Humanized anti-Factor Bb monoclonal antibody and Placebo in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Sanofi. Completed at 2 sites in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-22.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2023, 3 years 6 months ago, and no results have been posted to the registry.
  • Registered 2 years 4 months after the study started (first participant enrolled Oct 2021, registered Mar 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 68 studies in Hemoglobinuria, Paroxysmal with a site in United States — 10 open to participants now, 16 under way, 4 of them phase 3. Hemoglobinuria, Paroxysmal · United States.

Enrollment
27th of 54
54 · median 53
Started
2021
with 4 others
Phase 1
5 of 68
none open now
Registered
60th of 68
by date

Among the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States, this one is the 27th largest by enrollment of the 54 interventional ones that give a count, is one of 5 that started in 2021, is one of 5 in phase 1, and was the 60th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

10 of the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Hemoglobinuria, Paroxysmal with a site in United States, or all of them as a file.
02

Study summary

Primary objective

  • The tolerability and safety of SAR443809 Secondary
  • The PK parameters of SAR443809
  • The PD activity of SAR443809
  • The immunogenicity of SAR443809
Read the detailed description

Screening: up to 56 days (Day -56 to Day -2). Treatment: 1 day (treatment on Day 1, study observation period from Day -1 to Day 3). Follow-up and end of study: 105 days after IMP administration (follow up visits from Day 5 to Day 78; End of study visit on Day 106). Total study duration for each participant: approximately 23 weeks.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Having given written prior to undertaking any study-related procedure Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:

Any participant who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    SAR443809 and placebo dose 1 Arm

    6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 1

    Drug: Humanized anti-Factor Bb monoclonal antibody · Drug: Placebo

  • Experimental
    SAR443809 and placebo dose 2 Arm

    6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 2

    Drug: Humanized anti-Factor Bb monoclonal antibody · Drug: Placebo

  • Experimental
    SAR443809 and placebo dose 3 Arm

    6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 3

    Drug: Humanized anti-Factor Bb monoclonal antibody · Drug: Placebo

  • Experimental
    SAR443809 and placebo dose 4 Arm

    6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 4

    Drug: Humanized anti-Factor Bb monoclonal antibody · Drug: Placebo

  • Experimental
    SAR443809 and placebo dose 5 Arm

    6 participants receiving SAR443809 and 2 receiving placebo, subcutaneous administration dose 5

    Drug: Humanized anti-Factor Bb monoclonal antibody · Drug: Placebo

  • Experimental
    SAR443809 and placebo dose 6 Arm

    Optional: 6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 6

    Drug: Humanized anti-Factor Bb monoclonal antibody · Drug: Placebo

  • Experimental
    SAR443809 and placebo dose 7 Arm

    Optional: 6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 7

    Drug: Humanized anti-Factor Bb monoclonal antibody · Drug: Placebo

Interventions

  • DrugHumanized anti-Factor Bb monoclonal antibody

    Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration

    Also known as: SAR443809

  • DrugPlacebo

    Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)/treatment-emergent adverse events (TEAEs)

    Time frame: Baseline up to 23 weeks

  2. Incidence of potentially Clinical laboratory abnormalities

    Time frame: Baseline up to 23 weeks

Secondary outcomes

  1. PK parameters of SAR443809 for IV and SC administrations: Maximum plasma concentration observed (Cmax

    Time frame: Baseline up to 23 weeks

  2. PK parameters of SAR443809 for IV and SC administrations: First time to reach Cmax (tmax

    Time frame: Baseline up to 23 weeks

  3. PK parameters of SAR443809 for IV and SC administrations: Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to tlast (AUClast)

    Time frame: Baseline up to 23 weeks

  4. PK parameters of SAR443809 for IV and SC administrations: Area under the plasma concentration versus time curve extrapolated to infinity (AUC0-∞)

    Time frame: Baseline up to 23 weeks

  5. PK parameters of SAR443809 for IV and SC administrations: Terminal half-life associated with the terminal slope (λz) (t1/2z)

    Time frame: Baseline up to 23 weeks

  6. PK parameters of SAR443809 for IV and SC administrations: Time corresponding to the last concentration above the limit of quantification (Clast tlast)

    Time frame: Baseline up to 23 weeks

  7. PK parameters of SAR443809 for IV and SC administrations: total body clearance of a drug from the plasma calculated by dividing dose by AUC (CL)

    Time frame: Baseline up to 23 weeks

  8. PK parameters of SAR443809 for SC administrations: apparent total body clearance of the SC formulation (CL/F)

    Time frame: Baseline up to 23 weeks

  9. PK parameters of SAR443809 for IV and SC administrations: volume of distribution at steady-state (Vss)

    Time frame: Baseline up to 23 weeks

  10. PK parameters of SAR443809 for SC administrations: apparent volume of distribution at steady-state (Vss/F)

    Time frame: Baseline up to 23 weeks

  11. PK parameters of SAR443809 for SC administrations: absolute bioavailability (F)

    Time frame: Baseline up to 23 weeks

  12. Complement alternative pathway activity (Wieslab AP and alternative pathway hemolytic activity [AH50])

    Ex vivo activity of the alternative pathway of complement in serum using the WIESLAB® Complement System Alternative Pathway kit and a hemolytic assay (AH50)

    Time frame: Baseline up to 23 weeks

  13. Complement classical pathway activity (Wieslab CP)

    Ex vivo activity of the alternative pathway of complement in serum using the WIESLAB® Complement System Classical Pathway kit

    Time frame: Baseline up to 23 weeks

  14. Incidence of treatment -emergent Anti-SAR443809 antibodies

    Time frame: Baseline up to 23 weeks

07

Study locations

2 sites
  • Parexel International Site Number : 8400002
    Glendale, California 91206, United States
  • Parexel International Site Number : 8400003
    Baltimore, Maryland 21255, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in May 2023, 18 months.

Of 19 phase 1 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's 18 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2024
First posted
Mar 22, 2024
StartActual
Oct 11, 2021
Primary completionActual
May 5, 2023
CompletionActual
May 5, 2023
Last update
Mar 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06326814
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 22, 2024
Start date
Oct 11, 2021
Primary completion
May 5, 2023
Completion
May 5, 2023
Last update
Mar 22, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion